The National Advisory Committee on Immunization (NACI) caused some confusion earlier this month when it said the viral vector shot from AstraZeneca is not the 'preferred' product given its associated risk of vaccine-induced immune thrombotic thrombocytopenia (VITT) - a condition that causes blood clots. but some scientists say there's reason to believe that administering two doses of different products could boost a person's immune response beyond what can be achieved by giving the same shot twice.
As some experts continue to warn of very rare side effects associated with the AstraZeneca vaccine, Canadian health officials are now reviewing the research on mixing various COVID-19 shots.Ī study of a 'mismatched' vaccine regimen is underway in the U.K.
